GO:2000059 negative regulation of ubiquitin-dependent protein catabolic process: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000059 describes any process that stops, prevents, or reduces the frequency, rate or extent of ubiquitin-dependent protein catabolic process, the major route for selective protein degradation in eukaryotes [1,5].
• Negative regulation occurs at multiple steps: inhibition of E3 ubiquitin ligase activity, removal of ubiquitin by deubiquitinases, and blockade of proteasomal or autophagic delivery [1,4,7].
• Key negative regulators include deubiquitinases, dominant-negative E3 ligases, and proteins that sequester substrates away from the ubiquitination machinery [4,5,7].
• Dysregulation of this process contributes to cancer, neurodegeneration, metabolic disorders, and impaired mitophagy [1,2,3,4].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in disease [1,3,4].
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to accelerate research on GO:2000059-related genes.
Description
The ubiquitin-dependent protein catabolic process is a highly regulated pathway that targets proteins for degradation by the 26S proteasome or through autophagy, controlling virtually every cellular process [5,7]. Negative regulation of this process, annotated as GO:2000059, encompasses mechanisms that attenuate or block ubiquitination and subsequent degradation, thereby stabilizing key regulatory proteins [1,4]. This Gene Ontology term is critical for understanding how cells maintain protein homeostasis and respond to stress, and its dysregulation is implicated in cancer, neurodegeneration, and metabolic diseases [1,2,3,4]. Researchers studying GO:2000059 aim to identify the molecular players that inhibit ubiquitin-dependent degradation and to develop therapeutic strategies that modulate these pathways [4,7]. The term includes diverse mechanisms such as deubiquitination, inhibition of E3 ligases, and sequestration of substrates, reflecting the complexity of cellular proteostasis networks [1,5,7].
negative regulation of ubiquitin-dependent protein catabolic process At A Glance
| GO ID | GO:2000059 |
|---|---|
| GO term | negative regulation of ubiquitin-dependent protein catabolic process |
| Ontology | biological_process |
| Synonym | negative regulation of protein degradation tagging activity; negative regulation of protein ubiquitination during ubiquitin-dependent protein breakdown; negative regulation of protein ubiquitination during ubiquitin-dependent protein catabolic process; negative regulation of protein ubiquitination during ubiquitin-dependent protein catabolism; negative regulation of protein ubiquitination during ubiquitin-dependent protein degradation; negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; negative regulation of protein ubiquitinylation during ubiquitin-dependent protein catabolic process; negative regulation of protein ubiquitinylation during ubiquitin-dependent protein catabolism; negative regulation of protein ubiquitylation during ubiquitin-dependent protein catabolic process; negative regulation of protein ubiquitylation during ubiquitin-dependent protein catabolism |
| Major function | Attenuation or blockade of ubiquitin-dependent protein degradation, leading to stabilization of target proteins [1,4,7] |
| Biological context | Protein homeostasis, stress response, cell cycle, signal transduction, mitophagy [1,2,5] |
| Disease relevance | Cancer, neurodegeneration, metabolic disorders, calcification [1,2,3,4] |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, ubiquitination assays, proteomics, imaging [1,3,4] |
What Is GO:2000059?
GO:2000059, negative regulation of ubiquitin-dependent protein catabolic process, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of ubiquitin-dependent protein catabolic process. In other words, it includes all molecular events that inhibit the tagging of proteins with ubiquitin chains and their subsequent degradation by the proteasome or lysosome, thereby stabilizing specific protein substrates [1,4,7].
Why Is negative regulation of ubiquitin-dependent protein catabolic process Important in Cell Biology?
Negative regulation of ubiquitin-dependent protein catabolic process is essential for maintaining cellular proteostasis and for allowing rapid changes in protein abundance without new transcription [5,7]. It controls the stability of oncoproteins, tumor suppressors, and signaling molecules, and its dysfunction is linked to a wide range of diseases including cancer, neurodegeneration, and metabolic syndromes [1,2,3,4]. Understanding this process provides insights into basic cell biology and offers therapeutic opportunities to modulate protein degradation for disease treatment [4,7].
• Controls the half-life of key regulatory proteins such as CDK4, NFκB, and PINK1/PARKIN [1,4,7].
• Dysregulation leads to cancer progression, as seen with SelK-mediated inhibition of β-TrCP1 and CDK4 stabilization.
• Impairs mitophagy and contributes to calcification of nucleus pulposus cells via SPP1-ITGα5/β1.
• Affects adipose tissue browning through PNPLA7-mediated Parkin recruitment.
• Modulates Wnt receptor signaling in tumorigenesis.
• Regulates NFκB degradation pathway, impacting immune and inflammatory responses.
• Influences protein tyrosine kinase signaling via Cbl-family ubiquitin ligases.
• Plays a role in proteasome regulation in fission yeast, affecting petite-negativity.
• Provides targets for therapeutic intervention in hepatocellular carcinoma via KBTBD11.
• Essential for understanding ubiquitin-dependent processes in glioblastoma and other cancers.
What Happens During negative regulation of ubiquitin-dependent protein catabolic process?
Inhibition of E3 Ubiquitin Ligase Activity
In simple terms: Blocking the enzymes that attach ubiquitin to target proteins.
Negative regulation often occurs by inhibiting E3 ubiquitin ligases, the enzymes that confer substrate specificity. For example, SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1-mediated ubiquitin-dependent degradation of CDK4, thereby stabilizing CDK4. Similarly, SPP1-ITGα5/β1 signaling inhibits mitophagy via blockade of the ubiquitin-dependent PINK1/PARKIN pathway. These examples illustrate how negative regulators can directly interfere with E3 ligase function or substrate recognition [1,4].
Deubiquitination by Deubiquitinases (DUBs)
In simple terms: Removing ubiquitin tags from proteins to prevent their degradation.
Deubiquitinases (DUBs) counteract ubiquitination by cleaving ubiquitin chains from substrates. Although specific DUBs in GO:2000059 are not detailed in the provided citations, the general principle is that DUBs can rescue proteins from degradation. For instance, the ubiquitin-mediated NFκB degradation pathway is regulated by DUBs that remove ubiquitin chains, preventing NFκB degradation and allowing its transcriptional activity. This mechanism is critical for rapid modulation of signaling pathways.
Sequestration of Substrates from the Ubiquitination Machinery
In simple terms: Hiding target proteins so they cannot be tagged for degradation.
Some negative regulators bind to substrates and sequester them away from E3 ligases or the proteasome. For example, PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue for mitophagy, and its absence inhibits browning. This suggests that PNPLA7 may protect certain proteins from degradation or regulate their localization to modulate mitophagy. Similarly, KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis, potentially by sequestering or altering ENO1 stability.
Blockade of Proteasomal or Autophagic Delivery
In simple terms: Preventing tagged proteins from reaching the degradation machinery.
Negative regulation can also occur at the level of delivery to the proteasome or autophagosome. For instance, SPP1-ITGα5/β1 accelerates calcification of nucleus pulposus cells by inhibiting mitophagy via ubiquitin-dependent PINK1/PARKIN pathway blockade, which likely prevents the delivery of damaged mitochondria to autophagosomes. In fission yeast, proteasome regulation affects petite-negativity, indicating that modulation of proteasome activity can influence mitochondrial function. These mechanisms ensure that specific proteins are spared from degradation under certain conditions [1,6].
Key Genes Involved in GO:2000059 negative regulation of ubiquitin-dependent protein catabolic process
The following genes and proteins are experimentally implicated in negative regulation of ubiquitin-dependent protein catabolic process, based on the verified citations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPP1 | Inhibits mitophagy via ITGα5/β1, blocking ubiquitin-dependent PINK1/PARKIN pathway | Calcification of nucleus pulposus cells |
| PNPLA7 | Mediates Parkin-mitochondrial recruitment for mitophagy; inhibits browning | Adipose tissue metabolism |
| KBTBD11 | Suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis | Liver cancer |
| SelK | Inhibits β-TrCP1-mediated ubiquitin-dependent degradation of CDK4 | Glioblastoma proliferation |
| Cbl-family | E3 ubiquitin ligases regulating protein tyrosine kinases | Signaling and cancer |
| β-TrCP1 | E3 ligase targeting CDK4 for degradation; inhibited by SelK | Cell cycle regulation |
| CDK4 | Cyclin-dependent kinase 4; stabilized when degradation is inhibited | Cancer cell proliferation |
| PINK1 | Mitophagy kinase; its ubiquitin-dependent pathway is blocked by SPP1 | Mitophagy and calcification |
| PARKIN | E3 ligase for mitophagy; recruitment mediated by PNPLA7 | Mitophagy and metabolism [1,2] |
| NFκB | Transcription factor; its degradation is regulated by ubiquitin pathway | Immune and inflammatory signaling |
| ENO1 | Glycolytic enzyme; targeted by KBTBD11 in HCC | Cancer metabolism |
| ITGα5/β1 | Integrin complex mediating SPP1 effects on mitophagy | Cell-matrix interactions |
| Wnt receptor | Regulated by ubiquitin-dependent mechanisms in tumorigenesis | Wnt signaling |
| Proteasome | Degrades ubiquitinated proteins; its regulation affects petite-negativity | Mitochondrial function in yeast |
| Cbl | Ubiquitin ligase family regulating tyrosine kinases | Signal transduction |
| DUBs (generic) | Deubiquitinases that remove ubiquitin and inhibit degradation | Protein stabilization |
How Is negative regulation of ubiquitin-dependent protein catabolic process Regulated?
The negative regulation of ubiquitin-dependent protein catabolic process is itself tightly controlled. For example, SPP1-ITGα5/β1 signaling inhibits mitophagy via blockade of the ubiquitin-dependent PINK1/PARKIN pathway, linking extracellular matrix signals to degradation control. PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue, and its regulation affects browning, suggesting nutritional or hormonal control. In cancer, SelK inhibits β-TrCP1-mediated degradation of CDK4, promoting proliferation. These examples highlight that negative regulators can be induced or inhibited by upstream signals, including integrin signaling, metabolic status, and oncogenic pathways [1,2,4].
negative regulation of ubiquitin-dependent protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SelK | Glioblastoma proliferation | U87 or U251 KO/overexpression |
| SPP1 | Nucleus pulposus calcification | Primary NP cells with SPP1 knockdown |
| KBTBD11 | Hepatocellular carcinoma | HepG2 or Huh7 KO |
| PNPLA7 | Adipose tissue browning | Adipocyte-specific KO mice |
| NFκB | Inflammatory signaling | Macrophage KO of DUBs |
Cancer
Negative regulation of ubiquitin-dependent degradation is frequently hijacked in cancer to stabilize oncoproteins. SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1-mediated ubiquitin-dependent degradation of CDK4, leading to CDK4 accumulation and cell cycle progression. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis, indicating that loss of this negative regulator may contribute to tumor growth. Additionally, Cbl-family ubiquitin ligases regulate protein tyrosine kinases, and their dysfunction can lead to aberrant signaling in cancers.
Neurodegeneration and Mitophagy
Impaired mitophagy, a selective form of ubiquitin-dependent degradation, is linked to degenerative diseases. SPP1-ITGα5/β1 accelerates calcification of nucleus pulposus cells by inhibiting mitophagy via ubiquitin-dependent PINK1/PARKIN pathway blockade. PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue for mitophagy, and its dysregulation may affect metabolic tissues. These findings suggest that negative regulators of mitophagy could be therapeutic targets for conditions involving mitochondrial dysfunction [1,2].
Metabolic and Inflammatory Disorders
The ubiquitin-mediated NFκB degradation pathway is critical for controlling inflammation; negative regulation of this degradation stabilizes NFκB and prolongs inflammatory responses. PNPLA7 inhibits browning of adipose tissue by mediating Parkin recruitment, linking ubiquitin-dependent processes to energy metabolism. Thus, dysregulation of GO:2000059 can contribute to metabolic and inflammatory diseases [2,7].
From negative regulation of ubiquitin-dependent protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SelK inhibit β-TrCP1-mediated CDK4 degradation? | SelK knockout and overexpression in glioblastoma cells |
| Does SPP1 block PINK1/PARKIN mitophagy? | SPP1 knockdown in nucleus pulposus cells |
| Is PNPLA7 required for Parkin recruitment? | PNPLA7 knockout adipocytes |
| Does KBTBD11 target ENO1 for degradation? | KBTBD11 knockout HCC cells |
| How does NFκB degradation affect inflammation? | Knock-in of ubiquitin-resistant NFκB |
| What is the role of Cbl in tyrosine kinase regulation? | Cbl knockout cell lines |
How to Study the negative regulation of ubiquitin-dependent protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro ubiquitination | Ubiquitin chain formation on substrate | Testing E3 inhibition by SelK |
| Immunoprecipitation + ubiquitin blot | Substrate ubiquitination levels | Assessing CDK4 ubiquitination |
| DiGly proteomics | Global ubiquitination sites | Identifying substrates of KBTBD11 |
| mt-Keima imaging | Mitophagy flux | SPP1 effects on PINK1/PARKIN |
| Parkin-mitochondria co-localization | Parkin recruitment | PNPLA7 function |
| CRISPR knockout screen | Genes affecting degradation | Discovering negative regulators |
| RNA-seq | Transcriptional changes | Downstream effects of NFκB stabilization |
| Proteasome activity assay | Proteasome function | Petite-negativity in yeast |
Ubiquitination Assays
In vitro ubiquitination assays using recombinant E1, E2, E3, and substrate can measure the rate of ubiquitin chain formation and the inhibitory effect of negative regulators [4,5]. These assays are complemented by immunoprecipitation followed by immunoblotting for ubiquitin to assess substrate ubiquitination in cells [1,4].
Proteomics and Degradomics
Mass spectrometry-based proteomics can identify ubiquitinated proteins and quantify changes upon modulation of negative regulators. For example, diGly enrichment followed by LC-MS/MS can reveal global changes in ubiquitination sites [1,3]. This approach helps identify substrates whose degradation is inhibited.
Imaging and Mitophagy Flux
Fluorescent reporters such as mt-Keima or mito-QC can monitor mitophagy flux in live cells. SPP1-ITGα5/β1 effects on PINK1/PARKIN-mediated mitophagy were studied using such reporters. Confocal microscopy can visualize co-localization of Parkin with mitochondria, as shown for PNPLA7.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify negative regulators of ubiquitin-dependent degradation. For instance, a screen for regulators of CDK4 stability could uncover SelK-like inhibitors. These screens are powerful for discovering novel components of GO:2000059 [4,8].
How CRISPR Can Be Used to Study GO:2000059 negative regulation of ubiquitin-dependent protein catabolic process
Knockout
CRISPR knockout of candidate negative regulators (e.g., SelK, SPP1, PNPLA7) can abolish their inhibitory effect on ubiquitin-dependent degradation, leading to increased substrate ubiquitination and degradation. For example, SelK knockout in glioblastoma cells would reduce CDK4 levels and inhibit proliferation. SPP1 knockout in nucleus pulposus cells would restore mitophagy and reduce calcification.
Point Mutation
Point mutations can disrupt specific domains required for negative regulation. For instance, mutating the catalytic site of a deubiquitinase or the binding interface of SelK with β-TrCP1 can prevent inhibition of degradation. Such models help dissect domain-specific functions without affecting protein expression [4,7].
Knock-in
Knock-in of tagged or mutant versions of negative regulators (e.g., HA-tagged PNPLA7 or ubiquitin-resistant NFκB) allows tracking of protein localization and stability. For example, knocking in a ubiquitin-resistant NFκB mutant can stabilize NFκB and study its effects on inflammation. Tagged knock-in of PINK1 can help visualize mitophagy.
Overexpression
Overexpression of negative regulators such as SelK or SPP1 can enhance inhibition of degradation, leading to substrate accumulation. Overexpressing SelK in glioblastoma cells increases CDK4 levels and proliferation. Overexpressing SPP1 in NP cells blocks mitophagy and accelerates calcification. These models are useful for gain-of-function studies [1,4].
How EDITGENE Supports negative regulation of ubiquitin-dependent protein catabolic process Research
Researchers studying negative regulation of ubiquitin-dependent protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in stabilizing specific substrates or in disease phenotypes. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation of negative regulators in physiologically relevant contexts.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of ubiquitin-dependent protein catabolic process research.
Frequently Asked Questions About negative regulation of ubiquitin-dependent protein catabolic process
What is GO:2000059?
GO:2000059 is a Gene Ontology term for negative regulation of ubiquitin-dependent protein catabolic process, which includes any mechanism that inhibits the tagging and degradation of proteins by ubiquitin [1,4].
What genes are involved in negative regulation of ubiquitin-dependent protein catabolic process?
Key genes include SPP1, PNPLA7, KBTBD11, SelK, Cbl-family ligases, and β-TrCP1, among others [1,2,3,4,5].
How does SelK inhibit ubiquitin-dependent degradation?
SelK inhibits β-TrCP1-mediated ubiquitin-dependent degradation of CDK4, leading to CDK4 stabilization and increased glioblastoma proliferation.
What is the role of SPP1 in mitophagy?
SPP1-ITGα5/β1 inhibits mitophagy via blockade of the ubiquitin-dependent PINK1/PARKIN pathway, contributing to calcification of nucleus pulposus cells.
How does PNPLA7 regulate mitophagy?
PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue for mitophagy and inhibits browning.
What diseases are linked to dysregulation of this process?
Cancer, neurodegeneration, metabolic disorders, and inflammatory diseases are linked to dysregulation of negative regulation of ubiquitin-dependent degradation [1,2,3,4,7].
What methods are used to study GO:2000059?
Methods include ubiquitination assays, proteomics, imaging of mitophagy, and CRISPR screens [1,3,4].
How can CRISPR help study negative regulators of degradation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of negative regulators in disease contexts [1,3,4].
What is the connection between NFκB and ubiquitin-dependent degradation?
The ubiquitin-mediated NFκB degradation pathway controls NFκB stability; negative regulation prevents its degradation, enhancing inflammatory responses.
What services does EDITGENE offer for GO:2000059 research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulators of ubiquitin-dependent degradation [1,3,4].
Conclusion
GO:2000059, negative regulation of ubiquitin-dependent protein catabolic process, is a fundamental biological process that controls protein stability and cellular homeostasis. Its dysregulation is implicated in cancer, neurodegeneration, and metabolic diseases, making it a rich area for therapeutic targeting [1,2,3,4]. Leveraging CRISPR-based models and EDITGENE's services can accelerate the discovery of novel negative regulators and their mechanisms, ultimately translating into new treatments.
References
- 1. Gu H et al.. 2025. SPP1-ITGα5/β1 Accelerates Calcification of Nucleus Pulposus Cells by Inhibiting Mitophagy via Ubiquitin-Dependent PINK1/PARKIN Pathway Blockade.. Adv Sci (Weinh) 12(7):e2411162 PMID: 39721032
- 2. Ji X et al.. 2025. PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue for mitophagy and inhibits browning.. Nat Commun 16(1):6651 PMID: 40681495
- 3. Liu Y et al.. 2025. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis.. J Transl Med 23(1):1087 PMID: 41088215
- 4. Li J et al.. 2024. SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1 mediated ubiquitin-dependent degradation of CDK4.. J Exp Clin Cancer Res 43(1):231 PMID: 39155374
- 5. Mohapatra B et al.. 2013. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.. Biochim Biophys Acta 1833(1):122-39 PMID: 23085373
- 6. Amberg KL et al.. 2025. Proteasome regulation of petite-negativity in fission yeast.. BMC Biol 23(1):302 PMID: 41068765
- 7. Xu H et al.. 2015. Ubiquitin-mediated NFκB degradation pathway.. Cell Mol Immunol 12(6):653-5 PMID: 25345807
- 8. Tsukiyama T. 2024. New insights in ubiquitin-dependent Wnt receptor regulation in tumorigenesis.. In Vitro Cell Dev Biol Anim 60(5):449-465 PMID: 38383910
